Cell and Gene Therapy Catapult

Horiba has announced its participation in a new consortium formed to accelerate the development of process analytical technologies (PAT) in cell and gene therapy manufacturing. Horiba’s new A-TEEM Molecular Fingerprinting technology has shown great promise for fast QC/QA of complex biological systems and is a core technology being assessed for reducing batch failures and manufacturing […]

Cell and Gene Therapy Catapult (CGT Catapult) has announced that GSK will leverage the CGT Catapult Stevenage facility in the UK to perform GMP cell processing to accelerate its cell and gene therapy pipeline for clinical trials. Through this agreement, GSK will improve its GMP cell processing network to advance its early stage pipeline and […]

The Cell and Gene Therapy Catapult (CGT Catapult) has published today the 2020 Advanced Therapy Medicinal Product (ATMP) clinical trials database and report, which show a marked 20% growth in the number of ATMP clinical trials across the UK. The number of commercially sponsored trials has shown a dramatic surge since 2019, with an almost […]

The Cell and Gene Therapy Catapult (CGT Catapult) and Hertfordshire Local Enterprise Partnership (LEP) in the UK have announced that a new cell and gene therapy integration laboratory at the CGT Catapult facility in Stevenage will be part-funded by the government’s Getting Building Fund. The new laboratory will be exclusively dedicated to the provision of […]

The UK Department for International Trade (DIT) has classified Stevenage in the UK, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected to help attract further overseas […]